参考资料: [1] Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer. Retrieved October 20, 2023 from https://www.merck.com/news/...
The five-year survival rate for patients diagnosed with gastric cancer at an advanced stage is only 6%. About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) ther...
at which point they face a poor prognosis with a five-year survival rate of 6%,” said Dr. Zev A. Wainberg, professor of medicine at University of California, Los Angeles School of Medicine and co-director of the UCLA GI Oncology Program. “This approval ofpembrolizumabplus c...
Merck and Eisai announced today that KEYTRUDA®, an anti-PD-1 therapy, in combination with LENVIMA with respective clinical criteria and conditions for adult patients with advanced (not amenable to curative surge...
and overall survival (OS), reducing the risk of death by 34% (HR=0.66 [95% CI, 0.49-0.88]; p=0.0049) versus sunitinib. Median OS was not reached at the time of analysis in either study arm. The objective response rate ...
In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients over a wide range of cancer types. But it’s important to know that these cancer treatments do not work for everyone. The success rate of Keytruda depends...
“The majority of patients with gastric cancer are diagnosed at an advanced stage, at which point they face a poor prognosis with a five-year survival rate of 6%,” said Dr. Zev A. Wainberg, professor of medicin...
原文出处:KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer ...
Pembrolizumab (Keytruda) plus chemotherapy as first-line treatment significantly improved overall survival (OS) for patients with metastatic triple-negative breast cancer (TNBC) whose tumors express a certain level of PD-L1, according to results from the KEYNOTE-355 trial. ...
Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer. https://meetinglibrary./record/170580/abstract Background: Pembrolizumab (PEM), an anti-PD-1 antibody, is approved foradvanced urothelial cancer in the second-line setting (objective response rate[ORR] 21%) and in the firs...